Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193206 · ClinicalTrials.gov registry record · Phase 2
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT00193206 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 123 participants.
The verdict
NCT00193206, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
Interventions
- DRUG Gemcitabine
- DRUG Epirubicin
- DRUG Albumin-bound Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193206
The ClinicalTrials.gov registry entry for NCT00193206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00193206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193206 about?
NCT00193206 is a clinical study titled "Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer". In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
What is the current status of trial NCT00193206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2005-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00193206?
The interventions under investigation include: Gemcitabine (DRUG), Epirubicin (DRUG), Albumin-bound Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00193206?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.